FDA Commissioner Marty Makary called these changes “common-sense reforms” that could expedite the development of cell and ...

TOKYO & MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--BrightPath Bio (Tokyo Stock Exchange Growth 4594, “BrightPath”), a pioneer in iPS cell-derived Natural Killer T (“NKT”) cell therapy, and ...

With more than $80 million in hand, the University of Texas MD Anderson Cancer Center has launched its own cell therapy institute. Dubbed the Institute for Cell Therapy Discovery & Innovation, the ...

(Reuters) -Novo Nordisk has decided to discontinue its cell therapy research and development efforts, a spokesperson for the Danish drugmaker told Reuters on Friday. Bloomberg News first reported on ...

Cell and gene therapy are revolutionary approaches to treating diseases at the molecular level. They involve the manipulation ...

As the CSO for genomic medicine at Cytiva, I have numerous interactions with our customers, and I attend many scientific and industry events. It’s great to be able to get first-hand exposure to what ...

With cutting-edge technology, a robust regulatory framework, and a highly skilled team, BTCF is committed to driving innovation in cell therapy research and clinical translation, helping to bring next ...

CAR-T therapy is a major advance in cancer care, but high costs and centralized global manufacturing limit access.

Cell therapies, often described as ‘living therapies’, are transforming cancer treatment. These drugs harness the power of the immune system to deliver remarkable results, particularly for blood ...

On the heels of a recent cost-cutting drive that severed much of AmplifyBio’s R&D capacity, the Ohio-based contract manufacturing and research hybrid has hung up its hat for good. Amplify’s decision ...

Georgetown University's Lombardi Comprehensive Cancer Center researchers have identified a new way to reprogram T cells, ...